BFM
MXCT icon

Brooklands Fund Management’s MaxCyte MXCT Stock Holding History

Brooklands Fund Management’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.67M Buy
2,848,083
+658,063
+30% +$656K 2.87% 13
2026
Q1 		$1.54M Buy
+2,190,020
New +$2.04M 1.73% 17

Other funds holding MXCT

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Brooklands Fund Management's MXCT Position: Q2 2026 in Review

Brooklands Fund Management increased its MaxCyte (MXCT) stake by 30% in Q2 2026, buying an estimated $656K and bringing the position to 2,848,083 shares worth $3.67M. The position accounts for 2.87% of the portfolio, ranked #13.

Brooklands Fund Management first reported a position in MXCT in Q1 2026 and has held it in 2 quarters since. 123 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

  • Brooklands Fund Management held 2,848,083 shares of MaxCyte worth $3.67M as of Q2 2026.
  • Brooklands Fund Management bought 658,063 MaxCyte shares in Q2 2026, an estimated $656K.
  • MaxCyte made up 2.87% of Brooklands Fund Management's portfolio in Q2 2026, its #13 holding.
  • Brooklands Fund Management first reported a position in MaxCyte in Q1 2026 and has held it in 2 quarters since.
  • 123 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Brooklands Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.